Abstract
Mitochondrial enzymes monoamine oxidases were thought to be an emerging and useful therapeutic target for neurodegenerative disorders. Monoamine oxidases have two isoforms, A and B. MAO-A is related with metabolism of amine neurotransmitters in the brain whereas MAO-B is concerned with aging related neurodegenerative disorders. Therefore the identification, characterization and discovery of potent MAO-A and B inhibitors is very crucial in research. A series of quinolyl-thienyl chalcones were tested against MAO-A and B. Among the screened compounds, most of them revealed potent MAO-A and B inhibition. Compound 5i presented most potent MAO-A inhibition having IC50 values 0.047 µM, while 4l showed excellent inhibitory potency against MAO-B among all the tested compound having IC50 values 0.063 µM. Molecular modelling studies were performed against human MAO-A and MAO-B for the explanation of binding site interactions.
Keywords: Aging, molecular modelling, monoamine oxidase, neurodegenerative disease, quinolinyl-thienyl chalcones.
Medicinal Chemistry
Title:Quinolinyl-Thienyl Chalcones as Monoamine Oxidase Inhibitors and their In Silico Modeling Studies
Volume: 11 Issue: 6
Author(s): Sumera Zaib, Syed Umar Farooq Rizvi, Sana Aslam, Matloob Ahmad, Syed Mobasher Ali Abid, Mariya al-Rashida and Jamshed Iqbal
Affiliation:
Keywords: Aging, molecular modelling, monoamine oxidase, neurodegenerative disease, quinolinyl-thienyl chalcones.
Abstract: Mitochondrial enzymes monoamine oxidases were thought to be an emerging and useful therapeutic target for neurodegenerative disorders. Monoamine oxidases have two isoforms, A and B. MAO-A is related with metabolism of amine neurotransmitters in the brain whereas MAO-B is concerned with aging related neurodegenerative disorders. Therefore the identification, characterization and discovery of potent MAO-A and B inhibitors is very crucial in research. A series of quinolyl-thienyl chalcones were tested against MAO-A and B. Among the screened compounds, most of them revealed potent MAO-A and B inhibition. Compound 5i presented most potent MAO-A inhibition having IC50 values 0.047 µM, while 4l showed excellent inhibitory potency against MAO-B among all the tested compound having IC50 values 0.063 µM. Molecular modelling studies were performed against human MAO-A and MAO-B for the explanation of binding site interactions.
Export Options
About this article
Cite this article as:
Zaib Sumera, Rizvi Umar Farooq Syed, Aslam Sana, Ahmad Matloob, Ali Abid Mobasher Syed, al-Rashida Mariya and Iqbal Jamshed, Quinolinyl-Thienyl Chalcones as Monoamine Oxidase Inhibitors and their In Silico Modeling Studies, Medicinal Chemistry 2015; 11 (6) . https://dx.doi.org/10.2174/1573406410666141226131252
DOI https://dx.doi.org/10.2174/1573406410666141226131252 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Implications of Epigenetic Mechanisms and their Targets in Cerebral Ischemia Models
Current Neuropharmacology Insights Into Effects of Ellagic Acid on the Nervous System: A Mini Review
Current Pharmaceutical Design Arjunolic Acid: A Promising Antioxidant Moiety with Diverse Biological Applications
Current Organic Chemistry Double-Faced Role of Human Mesenchymal Stem Cells and their Role/Challenges in Cancer Therapy
Current Stem Cell Research & Therapy Designed Multiple Ligands: Basic Research vs Clinical Outcomes
Current Medicinal Chemistry Exploiting Substrate Recognition for Selective Inhibition of Protein Kinases
Current Pharmaceutical Design DNA Methyltransferase Inhibitors and their Therapeutic Potential
Current Topics in Medicinal Chemistry Subject Index to Volume 9
Current Pharmaceutical Design Quantitative Ultrasound of Orofacial Muscles in Infants from 6 Months to 5 Years: Collecting Normal Values
Current Medical Imaging Molecular Recognisation of 3a, 4-Dihydro-3-H-Indeno [1, 2-C] Pyrazole-2- Carboxamide/Carbothioamide Anticonvulsant Analogues Towards GABA-Aminotransferase- An in Silico Approach
Central Nervous System Agents in Medicinal Chemistry Infectious Agents and Neurodegenerative Diseases: Exploring the Links
Current Topics in Medicinal Chemistry DNA Repair in Premature Aging Disorders and Neurodegeneration
Current Aging Science Warming Up to New Possibilities with the Capsaicin Receptor TRPV1: mTOR, AMPK, and Erythropoietin
Current Neurovascular Research Targeting the Pleiotrophin/Receptor Protein Tyrosine Phosphatase β /ζ Signaling Pathway to Limit Neurotoxicity Induced by Drug Abuse
Mini-Reviews in Medicinal Chemistry Meet Our Associate Editor:
Current Molecular Medicine Long Non-coding RNA MALAT1 Inhibits Neuron Apoptosis and Neuroinflammation While Stimulates Neurite Outgrowth and Its Correlation With MiR-125b Mediates PTGS2, CDK5 and FOXQ1 in Alzheimer's Disease
Current Alzheimer Research Citicoline and Retinal Ganglion Cells: Effects on Morphology and Function
Current Neuropharmacology Targeting the Alpha 7 Nicotinic Acetylcholine Receptor to Reduce Amyloid Accumulation in Alzheimers Disease Pyramidal Neurons
Current Pharmaceutical Design Involvement of Rat Hippocampal Astrocytes in β-Amyloid-Induced Angiogenesis and Neuroinflammation
Current Alzheimer Research Molecular Players at the Intersection of Obesity and Osteoarthritis
Current Drug Targets